These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 3144825)
21. Circulating soluble immune complexes containing pseudomonas antigens in cystic fibrosis. Pitcher-Wilmott RW; Levinsky RJ; Matthew DJ Arch Dis Child; 1982 Aug; 57(8):577-81. PubMed ID: 6810763 [TBL] [Abstract][Full Text] [Related]
22. Extrapulmonary sites of Pseudomonas aeruginosa in adults with cystic fibrosis. Taylor RF; Morgan DW; Nicholson PS; Mackay IS; Hodson ME; Pitt TL Thorax; 1992 Jun; 47(6):426-8. PubMed ID: 1496501 [TBL] [Abstract][Full Text] [Related]
23. Monitoring clinical and microbiological evolution of a cystic fibrosis patient over 26 years: experience of a Brazilian CF Centre. da Costa Ferreira Leite C; Folescu TW; de Cássia Firmida M; Cohen RWF; Leão RS; de Freitas FAD; Albano RM; da Costa CH; Marques EA BMC Pulm Med; 2017 Jul; 17(1):100. PubMed ID: 28705217 [TBL] [Abstract][Full Text] [Related]
26. Urine products of bone breakdown as markers of bone resorption and clinical usefulness of urinary hydroxyproline: an overview. Simsek B; Karacaer O; Karaca I Chin Med J (Engl); 2004 Feb; 117(2):291-5. PubMed ID: 14975218 [TBL] [Abstract][Full Text] [Related]
27. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection. Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995 [TBL] [Abstract][Full Text] [Related]
28. Clinical and laboratory correlations in patients with cystic fibrosis and Pseudomonas aeruginosa infection: The experience of a regional centre. Smădeanu R; Moşescu S; Zăpucioiu C; Orăşeanu D Pneumologia; 2016; 65(4):201-6. PubMed ID: 29542902 [TBL] [Abstract][Full Text] [Related]
29. [Physiopathology of cystic fibrosis and of infections associated to this disease]. Aramă SS; Aramă V; Cercel AS; Ion DA; Hristea A; Sotcan M Pneumologia; 2007; 56(4):202-7. PubMed ID: 18320796 [TBL] [Abstract][Full Text] [Related]
30. Increased sputum amino acid concentrations and auxotrophy of Pseudomonas aeruginosa in severe cystic fibrosis lung disease. Thomas SR; Ray A; Hodson ME; Pitt TL Thorax; 2000 Sep; 55(9):795-7. PubMed ID: 10950901 [TBL] [Abstract][Full Text] [Related]
31. Progression of pulmonary disease after disappearance of Pseudomonas in cystic fibrosis. Sharma GD; Tosi MF; Stern RC; Davis PB Am J Respir Crit Care Med; 1995 Jul; 152(1):169-73. PubMed ID: 7599818 [TBL] [Abstract][Full Text] [Related]
32. Infection, inflammation, and lung function decline in infants with cystic fibrosis. Pillarisetti N; Williamson E; Linnane B; Skoric B; Robertson CF; Robinson P; Massie J; Hall GL; Sly P; Stick S; Ranganathan S; Am J Respir Crit Care Med; 2011 Jul; 184(1):75-81. PubMed ID: 21493738 [TBL] [Abstract][Full Text] [Related]
33. Comparison of 6 and 8 hourly tobramycin dosing intervals in treatment of pulmonary exacerbations in cystic fibrosis patients. Winnie GB; Cooper JA; Witson J; Cowan RG; Mayer D; Lepow M Pediatr Infect Dis J; 1991 May; 10(5):381-6. PubMed ID: 1906161 [TBL] [Abstract][Full Text] [Related]
34. Urinary excretion of hydroxylysyl glycosides during acute inflammation in the rat. Askenasi R; Le Lous M; Rao VH; Bazin S Clin Sci Mol Med; 1976 Mar; 50(3):195-7. PubMed ID: 1253529 [TBL] [Abstract][Full Text] [Related]
35. The success of the different eradication therapy regimens for Pseudomonas aeruginosa in cystic fibrosis. Emiralioglu N; Yalcin E; Meral A; Sener B; Dogru D; Ozcelik U; Kiper N J Clin Pharm Ther; 2016 Aug; 41(4):419-23. PubMed ID: 27311742 [TBL] [Abstract][Full Text] [Related]
36. Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients. Al-Aloul M; Crawley J; Winstanley C; Hart CA; Ledson MJ; Walshaw MJ Thorax; 2004 Apr; 59(4):334-6. PubMed ID: 15047956 [TBL] [Abstract][Full Text] [Related]
37. Phenazine content in the cystic fibrosis respiratory tract negatively correlates with lung function and microbial complexity. Hunter RC; Klepac-Ceraj V; Lorenzi MM; Grotzinger H; Martin TR; Newman DK Am J Respir Cell Mol Biol; 2012 Dec; 47(6):738-45. PubMed ID: 22865623 [TBL] [Abstract][Full Text] [Related]
38. Circulating immune complexes, antibodies to Pseudomonas aeruginosa, and pulmonary status in cystic fibrosis. Lagacé J; Mercier J; Fréchette M; Fournier D; Dubreuil M; Lamarre A; Lapointe JR; Montplaisir S J Clin Lab Immunol; 1989 Sep; 30(1):7-11. PubMed ID: 2534928 [TBL] [Abstract][Full Text] [Related]
39. Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. Assael BM Expert Rev Anti Infect Ther; 2011 Nov; 9(11):967-73. PubMed ID: 22029514 [TBL] [Abstract][Full Text] [Related]